Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant

Trial Profile

Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Pasireotide (Primary) ; Pegvisomant (Primary)
  • Indications Acromegaly
  • Focus Therapeutic Use
  • Acronyms PAPE
  • Most Recent Events

    • 15 Nov 2017 Results published in the Journal of Clinical Endocrinology and Metabolism
    • 10 Jun 2017 Biomarkers information updated
    • 04 Apr 2017 Preliminary results assessing safety and efficacy, presented at The 99th Annual Meeting of the Endocrine Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top